Protective immunity induced by live attenuated simian immunodeficiency virus

Current Opinion in Immunology

Volumn 10, Issue 4, 1998, Pages 436-443

  Johnson, R Paul ^a,b   Desrosiers, Ronald C ^a,c  

^a New England Regl Primate Res C   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c New England Regl Primate Res C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DELETION MUTANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MACACA; NONHUMAN; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0032146171     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80118-0     Document Type: Article

References (62)

1. + T-cell levels. AIDS. 7:1993;1159-1166.
2. + T cell counts.
3. of outstanding interest Connor RI, Kobber BTM, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 72:1998;1552-1576 This report analyses of 16 volunteers who were immunized with recombinant HIV gp120 subunit vaccines and later became infected with HIV. Comparison of vaccinees with appropriate controls revealed no differences in viral load, humoral or cellular immune response, or in the genetic sequence of the infecting HIV-1 strains.
4. Rowland-Jones S, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol. 7:1995;448-455.
5. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
6. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, Shearer GM. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 271:1994;42-46.
7. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1:1995;59-64.
8. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, Shearer GM. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 96:1995;867-876.
9. of special interest Mazzoli S, Trabattoni D, Caputo SL, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med. 3:1997;1250-1257 This analysis of HIV-seronegative partners of HIV-infected individuals demonstrates increased IL-2 production following in vitro stimulation with HIV antigens and increased levels of HIV-specific IgA in urine and vaginal wash samples.
10. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:1996;367-377.
11. Harrer T, Harrer E, Kalams SA, Barbosa P, Elbeik T, Feinberg M, Cao Y, Ho DD, Caliendo A, Johnson RP, et al. Strong cytotoxic T cells and weak neutralizing antibodies in non-progressing HIV-1 infection. AIDS Res Hum Retrovirus. 12:1996;585-592.
12. Rinaldo C, Huang X-L, Fan Z, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 69:1995;5838-5842.
13. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 332:1995;209-216.
14. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 332:1995;201-208.
15. Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol. 8:1990;557-578.
16. Schultz AM, Stott EJ. Primate models for AIDS vaccines. AIDS. 8:1994;S203-S212.
17. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 258:1992;1938-1941.
18. Wyand MS, Manson KH, Garcia-Moll M, Montefiori D, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol. 70:1996;3724-3733.
19. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet. 345:1995;1342-1344.
20. of special interest Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, Hall GA. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology. 229:1997;143-154 This reports that vaccination of rhesus macaques with the attenuated simian immunodeficiency virus (SIV) strain SIVmacC8 protected animals from protection with rectal challenge with either the pathogenic strain SIVmacJ5 or SHIV/HXB2, a recombinant of SIV and HIV that expresses the HXB2 envelope. SIV-specific cytotoxic T lymphocytes were found in peripheral blood and rectal lymphoid tissues of vaccinated animals.
21. Stahl-Hennig C, Dittmer U, NiBlein T, Petry H, Jurkiewicz E, Fuchs D, Wachter H, Matz-Rensing K, Kuhn E-M, Kaup F-J, et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol. 77:1996;2969-2981.
22. Kestler HW III, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 65:1991;651-662.
23. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol. 69:1995;5117-5123.
24. Dittmer U, Nisslein T, Bodemer W, Petry H, Sauermann U, Stahl HC, Hunsmann G. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology. 212:1995;392-397.
25. Marthas ML, Sutjipto S, Higgins J, Lohman B, Torten J, Luciw PA, Marx PA, Pedersen NC. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol. 64:1990;3694-3700.
26. Bogers WMJM, Niphuis H, Haaft PT, Laman JD, Koornstra W, Heeney JL. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS. 9:1995;F13-F18.
27. Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, et al. Protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol. 69:1995;2737-2744.
28. of special interest Miller CJ, McChesney MB, Lu X, Dailey PJ, Chutkowski C, Lu D, Brosio P, Roberts B, Lu Y. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol. 71:1997;1911-1921 This demonstrates that vaginal inoculation of macaques with the nonpathogenic SHIV 89.6, a recombinant of SIV and HIV, protected them from subsequent vaginal infection with the pathogenic SIV strain SIVmac239. Protection was associated with the presence of SIV-specific cytotoxic T lymphocytes in peripheral blood and SIV-specific antibodies in cervicovaginal secretions.
29. Quesada-Rolander M, Makitalo B, Thorstensson R, Zhang Y-J, Castanos-Velez E, Biberfeld G, Putkonen P. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV Type 1 envelope. AIDS Res Hum Retrovirus. 12:1992;993-999.
30. Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, Biberfeld G. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS. 4:1990;783-789.
31. 287 challenge. Virology. 242:1998;150-160.
32. Gibbs JS, Lackner AA, Lang SM, Simon MA, Sehgal PK, Daniel MD, Desrosiers RC. Progression of AIDS in the absence of a gene for vpr or vpx. J Virol. 69:1995;2378-2383.
33. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AM, Arthur LO, Johnson RP. Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol. 72:1998;1431-1437.
34. Burton DR. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA. 94:1997;10018-10023.
35. MD1. Although sterile immunity was not achieved, immunized animals had only low levels of SHIV DNA and never developed antibodies against the HIV-1 envelope.
36. Norley S, Beer B, Binninger-Schinzel D, Cosma C, Kurth R. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology. 219:1996;195-205.
37. Ilyinskii PO, Simon MA, Czajak SC, Lackner AA, Desrosiers RC. Induction of AIDS by simian immunodeficiency virus lacking NF-κB and SP1 binding elements. J Virol. 71:1997;1880-1887.
38. Ilyinskii PO, Daniel MD, Simon MA, Lackner AA, Desrosiers RC. The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys. J Virol. 68:1994;5933-5944.
39. Whitaker-Dowling P, Youngner JS. Viral interference-dominance of mutant viruses over wild-type virus in mixed infections. Microbiol Rev. 51:1987;179-191.
40. + T lymphocytes from vaccinated animals produced increased amounts of RANTES, macrophage inflammatory protein (MIP)-1α MIP-1β, factors other than these chemokines appeared to account for most of the MHC-unrestricted inhibition.
41. Reimann KA, Li JT, Veazey R, Halloran M, Park I-W, Karlsson GB, Sodroski J, Letvin NL. A chimeric simian/human immunodeficiency virus expressing a primary patient HIV-1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol. 70:1996;6922-6928.
42. Lohman BL, McChesney MB, Miller CJ, McGowan E, Joye SM, VanRompay KKA, Reay E, Antipa L, Pedersen NC, Marthas ML. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol. 68:1994;7021-7029.
43. of special interest Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, Mulligan MJ, Desrosiers RC. Induction of vigorous cytotoxic T lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol. 71:1997;7711-7718 This shows that immunization with attenuated SIV strains, SIVmac239Δnef or SIVmac239Δ3, results in a vigorous and durable SIV-specific CTL response, which can be detected for more than seven years after infection. CTL responses develop in the first four weeks of infection with either SIVmac239Δnef or SIVmac239Δ3 and appear to precede the onset of full protective immunity.
44. of special interest Almond N, Rose J, Sangster R, Silvera P, Stebbings R, Walker B, Stott EJ. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J Gen Virol. 78:1997;1919-1922 This demonstrates that transfer of immune serum from four macaques chronically infected with the attenuated SIV strain SIVmacC8 failed to protect two naive macaques from intravenous infection with pathogenic strain SIVmacJ5.
45. + CTLs.
46. Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol. 65:1997;277-346.
47. + nef-specific cytotoxic T cells in vaccinated macaques. Nat Med. 1:1995;1167-1173.
48. Bourgault I, Villefroy P, Beyer C, Aubertin AM, Levy JP, Venet A. Cytotoxic T-cell response and AIDS-free survival in simian immunodeficiency virus-infected macaques. AIDS. 7:1993;S73-S79.
49. Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, Desrosiers RC. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retrovirus. 10:1994;839-851.
50. Yasutomi Y, Koenig S, Woods RM, Madsen J, Wassef NM, Alving CR, Klein HJ, Nolan TE, Boots LJ, Kessler JA, et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol. 69:1995;2279-2284.
51. Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol. 70:1996;3978-3991.
52. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
53. Putkonen P, Makitalo B, Bottiger D, Biberfeld G, Thorstensson R. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol. 71:1997;4981-4984.
54. Quesada-Rolander M, Mäkitalo B, Thorstensson R, Zhang Y-J, Castaños-Velez E, Biberfeld G, Putkonen P. Protections against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res Hum Retrovirus. 12:1996;993-999.
55. Reimann KA, Li JT, Voss G, Lekutis C, Tenner-Racz K, Racz P, Lin W, Montefiori DC, Lee-Parritz DE, Lu Y, et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol. 70:1996;3198-3206.
56. + lymphocytes can control HIV replication in vitro by suppressing virus replication. Science. 234:1986;1563-1566.
57. Tsubota H, Lord CI, Watkins DI, Morimoto C, Letvin NL. A cytotoxic T lymphocyte inhibits AIDS virus replication in peripheral blood lymphocytes. J Exp Med. 169:1989;1421-1434.
58. + T cells. Science. 270:1995;1811-1815.
59. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med. 2:1996;767-775.
60. Burns DPW, Desrosiers RC. A caution of the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retrovirus. 8:1992;1189-1192.
61. of special interest Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol. 71:1997;5069-5079 This paper describes how animals infected with attenuated SIV strains develop changes in SIV-envelope-specific antibody responses over the first six to eight months of infection, as reflected by development of high titer antibodies to native envelope - antibodies that are resistent to dissociation with 8M urea - and changes in the ratio of antibodies to conformational and linear envelope epitopes. As assessed by these criteria, maturation of the antibody response temporally correlates with onset of full protective immunity.
62. Haigwood NL, Watson A, Sutton W, McClure J, Lewis J, Ranchalis J, Travis B, Voss G, Letvin N, Hu S-L, Hirsch VM. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett. 51:1996;107-114.